3 Key Takeaways
Plain English Summary- 01Core Finding
Effects were assessed by immunoglobulin levels, biochemical and histological fibrosis (tissue scarring) readouts, Olink analyses, RNA sequencing (RNA-Seq), and imaging mass cytometry (IMC).
- 02Study Evidence
Tested in a animal models + randomized controlled trial at the Phase I/II stage.
- 03Practical Meaning
Early-stage human studies — dosing, durability, and rare side effects still require Phase III confirmation.
What This Means for You
These findings highlight that FcRn blockers such as efgartigimod may have potential to simultaneously target autoimmune, inflammatory, and fibrotic features of SSc and highlight the potential of autoantibody-reducing therapies as disease-modifying approaches in SSc. A randomised, controlled Phase 2 trial with efgartigimod in SSc is currently ongoing.
The Discovery
Several autoantibodies promote inflammation and fibrosis (tissue scarring) in systemic sclerosis (SSc). Efgartigimod, engineered to block the neonatal fragment crystallisable (Fc) receptor (FcRn) and reduce immunoglobulin G (IgG) autoantibody levels, is approved for autoantibody-driven generalised myasthenia gravis and chronic inflammatory demyelinating neuropathy. FcRn blockade with murinised efgartigimod (mEfgartigimod) and an FcRn-blocking IgG1 Fc fragment was evaluated in the topoisomerase-I (TopoI)-induced mouse model of autoimmunity-driven fibrosis. Effects were assessed by immunoglobulin levels, biochemical and histological fibrosis readouts, Olink analyses, RNA sequencing (RNA-Seq), and imaging mass cytometry (IMC). Both prophylactic and therapeutic mEfgartigimod ameliorated dermal and pulmonary fibrosis in TopoI mice, comparably to nintedanib. Bulk RNA-Seq analysis demonstrated FcRn blockade with mEfgartigimod downregulated inflammatory, autoimmune, and fibrotic signalling pathways, with reduced expression of Ccl chemokines, tumour necrosis factor superfamily cytokines, and type I interferon (an immune-signaling protein) signalling components. IMC showed reduced accumulation of myofibroblasts, classically activated macrophages, dendritic cells, and T cells upon FcRn blockade. Single‑nucleus RNA-Seq revealed altered fibroblast-macrophage crosstalk, with decreases in myofibroblasts, inflammatory and neutrophil-like macrophages, and T cells with cell-type-specific transcriptional effects associated with reversal of profibrotic/inflammatory transcriptional programs. Consistent with these cellular changes, the circulating levels of Il1β and several chemokines were downregulated upon treatment, whereas antifibrotic mediators, such as Fgf21 and soluble Pd-l2, were upregulated.
How It Works, Simply
This immunology research focuses on inflammation · Antibodies · T cells. Researchers evaluated it using an animal models + Randomized controlled trial at the Phase I/II stage of medical research.
3 Key Takeaways
Clinical Takeaways- 01Core Finding
Effects were assessed by immunoglobulin levels, biochemical and histological fibrosis readouts, Olink analyses, RNA sequencing (RNA-Seq), and imaging mass cytometry (IMC).
- 02Study Evidence
Tested in a animal models + randomized controlled trial at the Phase I/II stage.
- 03Practical Meaning
Early-stage human studies — dosing, durability, and rare side effects still require Phase III confirmation.
Biological Mechanism & Study Design
Study Design & Cohort
Animal models + Randomized controlled trial
Animal models + Randomized controlled trial · Phase I/II
Biological Pathway & Modality
Inflammation · Antibodies · T cells
Intervention: Pharmaceutical blockade of the neonatal Fc receptor (FcRn) ameliorates autoimmunity
Experimental Findings & Endpoints
Several autoantibodies promote inflammation and fibrosis in systemic sclerosis (SSc).
Efgartigimod, engineered to block the neonatal fragment crystallisable (Fc) receptor (FcRn) and reduce immunoglobulin G (IgG) autoantibody levels, is approved for autoantibody-driven generalised myasthenia gravis and chronic inflammatory demyelinating neuropathy. FcRn blockade with murinised efgartigimod (mEfgartigimod) and an FcRn-blocking IgG1 Fc fragment was evaluated in the topoisomerase-I (TopoI)-induced mouse model of autoimmunity-driven fibrosis.
Effects were assessed by immunoglobulin levels, biochemical and histological fibrosis readouts, Olink analyses, RNA sequencing (RNA-Seq), and imaging mass cytometry (IMC). Both prophylactic and therapeutic mEfgartigimod ameliorated dermal and pulmonary fibrosis in TopoI mice, comparably to nintedanib.
Bulk RNA-Seq analysis demonstrated FcRn blockade with mEfgartigimod downregulated inflammatory, autoimmune, and fibrotic signalling pathways, with reduced expression of Ccl chemokines, tumour necrosis factor superfamily cytokines, and type I interferon signalling components. IMC showed reduced accumulation of myofibroblasts, classically activated macrophages, dendritic cells, and T cells upon FcRn blockade.
Single‑nucleus RNA-Seq revealed altered fibroblast-macrophage crosstalk, with decreases in myofibroblasts, inflammatory and neutrophil-like macrophages, and T cells with cell-type-specific transcriptional effects associated with reversal of profibrotic/inflammatory transcriptional programs. Consistent with these cellular changes, the circulating levels of Il1β and several chemokines were downregulated upon treatment, whereas antifibrotic mediators, such as Fgf21 and soluble Pd-l2, were upregulated.
Clinical Translation & Practice Context
These findings highlight that FcRn blockers such as efgartigimod may have potential to simultaneously target autoimmune, inflammatory, and fibrotic features of SSc and highlight the potential of autoantibody-reducing therapies as disease-modifying approaches in SSc.
A randomised, controlled Phase 2 trial with efgartigimod in SSc is currently ongoing.
The Bottom Line · Clinical Pearl
“These findings highlight that FcRn blockers such as efgartigimod may have potential to simultaneously target autoimmune, inflammatory, and fibrotic features of SSc and highlight the potential of autoantibody-reducing therapies as disease-modifying approaches in SSc.”
Published in Annals of the Rheumatic Diseases · Current Stage: Phase I/II
